MedTrace Logo

A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors

NCT05789537 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2025-03-11

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with Hemophilia B with inhibitors, as part of the SerpinPC registrational program.

Conditions

  • Hemophilia B with Inhibitor
  • Hemophilia B

Interventions

DRUG

SerpinPC

Administered as SC injection.

Sponsors & Collaborators

  • Centessa Pharmaceuticals plc

    collaborator INDUSTRY

  • ApcinteX Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-28
Primary Completion
2024-11-14
Completion
2025-02-24
FDA Drug
Yes

Countries

  • United States
  • Armenia
  • Australia
  • France
  • Germany
  • India
  • Italy
  • Spain
  • Taiwan
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05789537 on ClinicalTrials.gov